GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Prostatype Genomics AB (OSTO:PROGEN) » Definitions » Net Margin %

Prostatype Genomics AB (OSTO:PROGEN) Net Margin % : -25,459.52% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Prostatype Genomics AB Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Prostatype Genomics AB's Net Income for the six months ended in Dec. 2024 was kr-21.39 Mil. Prostatype Genomics AB's Revenue for the six months ended in Dec. 2024 was kr0.08 Mil. Therefore, Prostatype Genomics AB's net margin for the quarter that ended in Dec. 2024 was -25,459.52%.

The historical rank and industry rank for Prostatype Genomics AB's Net Margin % or its related term are showing as below:

OSTO:PROGEN' s Net Margin % Range Over the Past 10 Years
Min: -156300   Med: -8650.25   Max: -3055.68
Current: -20628.64


OSTO:PROGEN's Net Margin % is ranked worse than
98.6% of 214 companies
in the Medical Diagnostics & Research industry
Industry Median: -7.645 vs OSTO:PROGEN: -20628.64

Prostatype Genomics AB Net Margin % Historical Data

The historical data trend for Prostatype Genomics AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prostatype Genomics AB Net Margin % Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24
Net Margin %
Get a 7-Day Free Trial -11,548.65 -156,300.00 -4,258.71 -3,055.68 -20,628.64

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -3,899.28 -4,599.11 -2,299.23 -17,100.00 -25,459.52

Competitive Comparison of Prostatype Genomics AB's Net Margin %

For the Diagnostics & Research subindustry, Prostatype Genomics AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prostatype Genomics AB's Net Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where Prostatype Genomics AB's Net Margin % falls into.


;
;

Prostatype Genomics AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Prostatype Genomics AB's Net Margin for the fiscal year that ended in Dec. 2024 is calculated as

Net Margin=Net Income (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-41.051/0.199
=-20,628.64 %

Prostatype Genomics AB's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-21.386/0.084
=-25,459.52 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prostatype Genomics AB  (OSTO:PROGEN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Prostatype Genomics AB Net Margin % Related Terms

Thank you for viewing the detailed overview of Prostatype Genomics AB's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Prostatype Genomics AB Business Description

Traded in Other Exchanges
N/A
Address
Gustaf III:s Boulevard 34, Solna, SWE, 169 73
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.

Prostatype Genomics AB Headlines

No Headlines